Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Beigene Ltd (ADR)    BGNE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

BeiGene : Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO

share with twitter share with LinkedIn share with facebook
share via e-mail
09/29/2017 | 01:12pm CET

BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented preliminary data from the dose-verification portion of the ongoing Phase 1/2 trial of its investigational anti-PD-1 antibody BGB-A317 in Chinese patients with advanced solid tumors at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China. The preliminary data suggest that BGB-A317 was generally well tolerated and exhibited preliminary evidence of anti-tumor activity in a Chinese study population with advanced solid tumors. BeiGene and Celgene Corporation have a global strategic collaboration for BGB-A317 for solid tumors; BeiGene retains exclusive rights to BGB-A317 in China.

BGB-A317 was generally well tolerated and showed preliminary activity in a heavily pretreated study population with advanced solid tumors. At the time of the data cut-off, no dose-limiting toxicities were observed. The pharmacokinetic profile in Chinese patients was consistent with that reported in global trials of BGB-A317 at the registrational dose, commented Professor Lin Shen of the Peking University Cancer Hospital and Beijing Institute for Cancer Research, Beijing, China, the lead author of the abstract.

This dose-verification trial is an important step as we advance BGB-A317 along Chinas domestic innovative drug development pathway. Two registrational trials of BGB-A317, in urothelial cancer and classical Hodgkin lymphoma, are currently ongoing in China. The Celgene partnership allows us to increase our investment in BGB-A317, and we intend to initiate Phase 3 trials supporting approval in China for each of the four most common tumors in the country including lung, stomach, liver, and esophageal cancers, with the initial studies expected to start in the fourth quarter of 2017 or first quarter of 2018, commented Amy Peterson, MD, Chief Medical Officer, Immuno-oncology at BeiGene.

Summary of Results from the Ongoing Phase 1/2 Trial

The multi-center Phase 1/2 trial of BGB-A317 consists of a Phase 1 dose-verification portion and a Phase 2 portion of indication expansion in disease-specific cohorts. Data presented at CSCO include patients enrolled in the Phase 1 portion of this study, who received BGB-A317 at 200 mg once every three weeks (Q3W).

As of June 16, 2017, 20 patients had enrolled in the trial. The median duration of therapy in these patients was 53 days (range 21171 days).

Adverse events (AEs) assessed by the investigator to be related to treatment occurred in 19 patients (95%). The most common treatment-related AEs (TRAEs) were related to changes in clinical laboratory value; TRAEs occurring in 15% or more of patients included increased blood bilirubin (45%), anemia (35%), proteinuria (30%), increased aspartate transferase (AST) (25%), increased alanine transferase (ALT) (20%), leukopenia (15%), neutropenia (15%), pyrexia (15%), and vomiting (15%). All of the TRAE cases were grades 1 or 2 except for one case each of grade 3 increased blood bilirubin, leukopenia, and neutropenia. Increased AST (25%) and ALT (20%) were the most common AEs that were potentially immune related.

At the time of the data cutoff, 11 patients had at least one post-baseline imaging assessment, and three patients had at least two imaging assessments. The efficacy-evaluable population (measurable disease at baseline and at least one post-baseline tumor assessment, or progression or death) consisted of 12 patients, including three patients with microsatellite-instability-high (MSI-high) colorectal cancer (CRC), two patients with gastric cancer (GC), two patients with hepatocellular carcinoma (HCC), two patients with urothelial cancer (UC), two patients with melanoma, and one patient with gastrointestinal stromal tumor (GIST). Partial responses (PR) were observed in one patient with UC (confirmed) and one with GC (unconfirmed). Stable disease was observed in two patients with melanoma and one with MSI-high CRC. In the remaining eight patients who were not evaluable as of the data cutoff, a third unconfirmed PR was observed in a patient with esophageal cancer 11 days after the data cutoff. At the time of the data cutoff, 15 patients remained on treatment.

About BGB-A317

BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for BGB-A317 for solid tumors.

(c) 2017 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
CELGENE CORPORATION -0.33% 89.61 Delayed Quote.-13.85%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BEIGENE LTD (ADR)
03/08BEIGENE : to Present at Upcoming Investor Conferences
03/05BeiGene to Present at Upcoming Investor Conferences
03/01BEIGENE : Announces Approval of REVLIMID for Newly Diagnosed Multiple Myeloma in..
03/01BEIGENE : Management's Discussion and Analysis of Financial Condition and Result..
02/28BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Fin..
02/28BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
02/28BEIGENE : Announces Approval of REVLIMID for Newly Diagnosed Multiple Myeloma in..
02/28BEIGENE : gains expanded China label for Revlimid
02/28BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma ..
02/13BEIGENE : Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Uro..
More news
News from SeekingAlpha
02/28BeiGene misses by $0.40, misses on revenue 
02/20BIOTECHS : Still Well Placed For More Gains 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/13YOUR DAILY PHARMA SCOOP : A Look At Celldex, BeiGene Data, Axovant Announces Cha.. 
02/11WEEK IN REVIEW : Tsinghua University Invests $276 Million In Cambridge U.K. Bioh.. 
Financials ($)
Sales 2018 90,1 M
EBIT 2018 -328 M
Net income 2018 -369 M
Finance 2018 564 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 85,4x
EV / Sales 2019 65,0x
Capitalization 8 264 M
Duration : Period :
Beigene Ltd (ADR) Technical Analysis Chart | BGNE | US07725L1026 | 4-Traders
Technical analysis trends BEIGENE LTD (ADR)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 137 $
Spread / Average Target -12%
EPS Revisions
John V. Oyler Chairman & Chief Executive Officer
Maggie Liu Head-Operations
Howard Liang Chief Financial & Strategy Officer
Alice Kang Head-Clinical Development
Michael J. Goller Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE LTD (ADR)61.84%8 264
GILEAD SCIENCES11.31%104 156
GENMAB22.93%12 773
BLUEBIRD BIO INC12.18%10 729